Harnessing Human Tissue Models for Drug Development - New Research from Draper Share Article Research shows how organs-on-a-chip can test 96 tissue models at once. Draper and Pfizer used the PREDICT96 microenvironment to seed, grow and test human tissue models of the kidney, vasculature, liver and intestine. Credit: Draper. “Novel drug discovery efforts suffer from increasing costs and low probability of clinical trial success. Organ-on-chip technology has the potential to greatly aid the development of new therapies,” according to a new research paper led by Draper and Pfizer. CAMBRIDGE, Mass. (PRWEB) April 13, 2021 As models of organs on-a-chip (OOC) become major tools to aid drug discovery, toxicity screening and efficacy testing, scientists are making progress in developing clinically predictive test environments for these tiny tissue models. Now, a series of proof of concept experiments led by Draper and Pfizer has demonstrated progress toward that standard. Researchers have developed a high throughput OOC platform that expands the potential uses of OOC and positions it to more broadly improve disease research and drug development.